Is PALI or KALV more profitable?

Palisade Bio's return on equity of -36.79% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% KalVista Pharmaceuticals N/A -341.44% -111.94%

Is MLTX or PALI more profitable?

Palisade Bio's return on equity of -36.79% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Palisade Bio N/A -36.79% -34.34%

Does the media prefer MLTX or PALI?

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Palisade Bio. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat MoonLake Immunotherapeutics' score of 0.47 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PALI or CAPR more profitable?

Palisade Bio's return on equity of -36.79% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Capricor Therapeutics N/A -59.27% -48.65%

Does the media prefer PALI or CAPR?

In the previous week, Capricor Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Capricor Therapeutics and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat Capricor Therapeutics' score of -0.14 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or INBX more profitable?

Palisade Bio's return on equity of -36.79% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Inhibrx Biosciences N/A -563.90% -72.32%

Which has better valuation and earnings, XERS or PALI?

Xeris Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xeris Biopharma $314.85M 4.54 $550K $0.06 138.00 Palisade Bio $250K 1,458.07 -$16.78M -$1.01 N/A

Does the media favor XERS or PALI?

In the previous week, Xeris Biopharma had 6 more articles in the media than Palisade Bio. MarketBeat recorded 10 mentions for Xeris Biopharma and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat Xeris Biopharma's score of -0.12 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palisade Bio (PALI) Competitors

$2.10 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.10%)

As of 07/2/2026 07:58 PM Eastern

Compare

PALI vs. KALV, MLTX, CAPR, INBX, and XERS

Should you buy Palisade Bio stock or one of its competitors? MarketBeat compares Palisade Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palisade Bio include KalVista Pharmaceuticals (KALV), MoonLake Immunotherapeutics (MLTX), Capricor Therapeutics (CAPR), Inhibrx Biosciences (INBX), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Palisade Bio compare to KalVista Pharmaceuticals?

Palisade Bio (NASDAQ:PALI) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

In the previous week, Palisade Bio had 4 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 4 mentions for Palisade Bio and 0 mentions for KalVista Pharmaceuticals. Palisade Bio's average media sentiment score of 0.51 beat KalVista Pharmaceuticals' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Palisade Bio	Positive
KalVista Pharmaceuticals	Neutral

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Palisade Bio's return on equity of -36.79% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Palisade Bio has higher earnings, but lower revenue than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,458.07	-$16.78M	-$1.01	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Palisade Bio currently has a consensus price target of $8.83, suggesting a potential upside of 320.63%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 13.33%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Palisade Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Summary

Palisade Bio beats KalVista Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Palisade Bio compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Palisade Bio. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat MoonLake Immunotherapeutics' score of 0.47 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio's return on equity of -36.79% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Palisade Bio	N/A	-36.79%	-34.34%

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics currently has a consensus target price of $24.21, suggesting a potential upside of 27.78%. Palisade Bio has a consensus target price of $8.83, suggesting a potential upside of 320.63%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Palisade Bio	$250K	1,458.07	-$16.78M	-$1.01	N/A

Summary

Palisade Bio beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Palisade Bio compare to Capricor Therapeutics?

Palisade Bio (NASDAQ:PALI) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Capricor Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Capricor Therapeutics and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat Capricor Therapeutics' score of -0.14 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Palisade Bio's return on equity of -36.79% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Palisade Bio has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,458.07	-$16.78M	-$1.01	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Palisade Bio currently has a consensus target price of $8.83, indicating a potential upside of 320.63%. Capricor Therapeutics has a consensus target price of $53.67, indicating a potential upside of 131.22%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Palisade Bio is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Palisade Bio beats Capricor Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Palisade Bio compare to Inhibrx Biosciences?

Palisade Bio (NASDAQ:PALI) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Palisade Bio currently has a consensus price target of $8.83, suggesting a potential upside of 320.63%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 53.72%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Palisade Bio is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Palisade Bio had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 4 mentions for Palisade Bio and 0 mentions for Inhibrx Biosciences. Palisade Bio's average media sentiment score of 0.51 beat Inhibrx Biosciences' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Palisade Bio	Positive
Inhibrx Biosciences	Neutral

Palisade Bio has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

Palisade Bio's return on equity of -36.79% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Palisade Bio has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,458.07	-$16.78M	-$1.01	N/A
Inhibrx Biosciences	$1.30M	1,101.15	-$140.05M	-$8.39	N/A

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Palisade Bio beats Inhibrx Biosciences on 12 of the 16 factors compared between the two stocks.

How does Palisade Bio compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 30.43%. Palisade Bio has a consensus price target of $8.83, suggesting a potential upside of 320.63%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xeris Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, Xeris Biopharma had 6 more articles in the media than Palisade Bio. MarketBeat recorded 10 mentions for Xeris Biopharma and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.51 beat Xeris Biopharma's score of -0.12 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Palisade Bio's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Palisade Bio	N/A	-36.79%	-34.34%

Xeris Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	4.54	$550K	$0.06	138.00
Palisade Bio	$250K	1,458.07	-$16.78M	-$1.01	N/A

Summary

Xeris Biopharma beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$364.52M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-2.08	21.61	28.02	24.70
Price / Sales	1,458.07	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.41	8.66	10.96	6.46
Net Income	-$16.78M	$23.81M	$3.57B	$337.01M
7 Day Performance	11.11%	3.39%	2.12%	1.69%
1 Month Performance	20.69%	10.81%	5.25%	3.81%
1 Year Performance	189.66%	62.61%	33.29%	23.90%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	2.1054 of 5 stars	$2.10 flat	$8.83 +320.6%	+189.7%	$364.52M	$250K	N/A	10	Analyst Forecast Gap Down
KALV KalVista Pharmaceuticals	2.2506 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100
MLTX MoonLake Immunotherapeutics	3.2298 of 5 stars	$19.45 -2.3%	$23.85 +22.6%	-59.1%	$1.43B	N/A	N/A	2	Analyst Forecast Insider Trade
CAPR Capricor Therapeutics	2.0992 of 5 stars	$24.08 +1.2%	$53.67 +122.9%	+129.9%	$1.39B	$22.27M	N/A	101	Insider Trade
INBX Inhibrx Biosciences	1.9275 of 5 stars	$94.75 -0.8%	$150.00 +58.3%	+499.2%	$1.39B	$1.30M	N/A	166

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. KALV, MLTX, CAPR, INBX, and XERS

How does Palisade Bio compare to KalVista Pharmaceuticals?

Summary

How does Palisade Bio compare to MoonLake Immunotherapeutics?

Summary

How does Palisade Bio compare to Capricor Therapeutics?

Summary

How does Palisade Bio compare to Inhibrx Biosciences?

Summary

How does Palisade Bio compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. KALV, MLTX, CAPR, INBX, and XERS

How does Palisade Bio compare to KalVista Pharmaceuticals?

Does the media refer more to PALI or KALV?

Do insiders & institutionals believe in PALI or KALV?

Is PALI or KALV more profitable?

Which has better earnings & valuation, PALI or KALV?

Do analysts rate PALI or KALV?

Which has more volatility and risk, PALI or KALV?

Summary

How does Palisade Bio compare to MoonLake Immunotherapeutics?

Which has more volatility and risk, MLTX or PALI?

Does the media prefer MLTX or PALI?

Is MLTX or PALI more profitable?

Do insiders and institutionals hold more shares of MLTX or PALI?

Do analysts prefer MLTX or PALI?

Which has preferable earnings and valuation, MLTX or PALI?

Summary

How does Palisade Bio compare to Capricor Therapeutics?

Does the media prefer PALI or CAPR?

Which has more volatility and risk, PALI or CAPR?

Is PALI or CAPR more profitable?

Which has stronger earnings & valuation, PALI or CAPR?

Do institutionals and insiders believe in PALI or CAPR?

Do analysts recommend PALI or CAPR?

Summary

How does Palisade Bio compare to Inhibrx Biosciences?

Do analysts prefer PALI or INBX?

Does the media refer more to PALI or INBX?

Which has more volatility and risk, PALI or INBX?

Is PALI or INBX more profitable?

Which has stronger valuation and earnings, PALI or INBX?

Do insiders and institutionals believe in PALI or INBX?

Summary

How does Palisade Bio compare to Xeris Biopharma?

Do analysts recommend XERS or PALI?

Which has more volatility & risk, XERS or PALI?

Does the media favor XERS or PALI?

Do insiders & institutionals hold more shares of XERS or PALI?

Is XERS or PALI more profitable?

Which has better valuation and earnings, XERS or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools